What's in a Name? That Which We Call Immune Cells by Any Other Name Would All Smell as Sweet.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 35442426.
- Also identified by DOI 10.1158/1078-0432.CCR-22-0783.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In the FUTURE-C-Plus phase II trial, patients with advanced previously untreated immune-enriched triple-negative breast cancer achieved an overall objective response rate of 81.3% with the combination of camrelizumab, famitinib, and nab-paclitaxel. This supports that the quantity of immune cells is important for identifying those with response to treatments combined with PD-1-targeting immunotherapy. See related article by Chen et al., p. 2807.
Medical subject headings
- Triple Negative Breast Neoplasms